Navigating ISO 10993-1 Updates: A Guide for 2025/2026 Compliance

Navigating ISO 10993-1 Updates: A Guide for 2025/2026 Compliance ==================================================================== With significant updates to the ISO 10993-1 standard anticipated for 2025/2026, medical device manufacturers must strategically adapt their biocompatibility programs to ensure continued compliance and prevent submission delays. A proactive approach requires more than simply updating internal procedures; it involves a fundamental re-evaluation of the entire biological risk assessment framework. The anticipated changes will likely continue the shift away from a checklist-based testing approach and place even greater emphasis on a holistic, risk-based methodology grounded in deep material and chemical knowledge. For manufacturers, this means strategically preparing for a more rigorous justification process. The updates are expected to reinforce the importance of chemical characterization (ISO 10993-18) as a foundational step in evaluating device safety. This shift requires manufacturers to build a comprehensive narrative that connects material data, chemical analysis, and toxicological risk assessments to the overall patient risk profile, enabling well-justified decisions about which biological tests are—and are not—necessary. ### Key Points * **Shift to a Full Risk Management Process:** The updates will further solidify the move from a prescriptive testing matrix to a comprehensive biological risk assessment. The focus is on understanding *why* a device is safe, not just checking boxes on a test list. * **Chemical Characterization is Foundational:** A thorough understanding of a device's material composition and its chemical constituents, including process residuals and leachables, is becoming the starting point for all biocompatibility evaluations. Robust data from studies guided by ISO 10993-18 is critical. * **Documentation is Paramount:** The Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER) are not administrative documents. They must be robust, scientific narratives that detail the evaluation strategy, synthesize all available data, and present a clear, evidence-based argument for biological safety. * **Proactive Gap Analysis is Essential:** Manufacturers with existing products should conduct a gap analysis of their current biocompatibility data against the anticipated requirements of the updated standard to identify any deficiencies that could impact future regulatory submissions or device modifications. * **Early Regulatory Engagement De-Risks Submissions:** For devices with novel materials, borderline testing justifications, or complex risk profiles, engaging with regulatory bodies like the FDA through the Q-Submission program is a critical strategic step to gain alignment on the proposed biocompatibility evaluation strategy. ## Understanding the Core Shift: From Testing to Holistic Risk Assessment The evolution of ISO 10993-1 reflects a broader regulatory trend toward a more scientific, risk-based approach to device safety. Rather than simply conducting a pre-defined battery of tests based on device category and contact duration, manufacturers are expected to perform a comprehensive biological risk assessment. This process begins with a deep understanding of the device itself. The evaluation must consider: * **All Materials:** Every material component that comes into direct or indirect contact with the body. * **Manufacturing Processes:** The potential for process contaminants, residues (e.g., from sterilization or cleaning), or material changes during manufacturing. * **Intended Use:** The nature, duration, and frequency of body contact. * **Patient Population:** Any specific vulnerabilities of the intended users. The goal is to proactively identify potential biological hazards and then systematically gather the evidence needed to demonstrate that the risks are acceptable. This evidence may come from biological testing, but increasingly, it comes from a combination of material data, chemical characterization, and toxicological risk assessment. ## The Central Role of Chemical Characterization (ISO 10993-18) Under the evolving framework, chemical characterization is no longer just one option; it is the cornerstone of the biological evaluation. A robust chemical characterization program, guided by ISO 10993-18, provides the data needed to understand what substances could potentially be released from a device during its clinical use. ### What FDA Will Scrutinize 1. **Extraction Strategy:** Regulators will look for a scientifically sound justification for the extraction conditions used (e.g., solvents, temperature, duration). The conditions should be exhaustive or simulate the intended clinical use of the device. 2. **Analytical Techniques:** The analytical methods must be sufficiently sensitive and specific to detect, identify, and quantify potential leachables at levels relevant to patient safety. The analytical evaluation threshold (AET) must be properly calculated and justified. 3. **Toxicological Risk Assessment:** Once chemical constituents are identified, a toxicological risk assessment is required to evaluate the potential health impact of each substance at its measured exposure level. This assessment must be conducted by qualified toxicologists and should use established methodologies to derive tolerable intake levels. For a device with long-term tissue contact, such as a novel orthopedic implant, a rigorous analysis of extractables and leachables can provide powerful evidence to justify forgoing certain long-term in-vivo tests, such as carcinogenicity or chronic toxicity studies. However, this justification depends entirely on the quality and completeness of the chemical and toxicological data. ## Enhancing Your Biological Evaluation Plan (BEP) and Report (BER) The BEP and BER are the primary documents that communicate a manufacturer's biocompatibility strategy and conclusions to regulators. The anticipated updates will likely demand even more detail and a clearer, more integrated narrative within these documents. ### The Biological Evaluation Plan (BEP) The BEP is a forward-looking plan developed *before* any testing is initiated. It serves as the roadmap for the entire evaluation. A comprehensive BEP should include: * **Detailed Device Description:** Including all materials, manufacturing processes, and the intended clinical application. * **Identification of Potential Risks:** A systematic review of biological endpoints relevant to the device based on its nature and duration of contact. * **Proposed Evaluation Strategy:** A clear outline of the proposed plan, including: * Leveraging existing data (e.g., material supplier information, literature). * The plan for chemical characterization. * Justifications for any biological tests that will be omitted. * Protocols for any biological tests that will be performed. * **Information Gathering:** A summary of all physical and chemical information known about the device and its components. ### The Biological Evaluation Report (BER) The BER is the final summary document that synthesizes all collected information to form a concluding argument for the device's biological safety. It is a living document that should be updated whenever changes are made to the device or its manufacturing. A robust BER connects all the dots, explaining how the material data, chemical analysis, literature, and any biological test results collectively demonstrate that the device is safe for its intended use. ## Scenarios: Adapting to the Updated Standard ### Scenario 1: A Novel Orthopedic Implant with a New Surface Technology * **Challenge:** A long-term implantable device made with a material or surface coating that has limited or no history of use in medical devices. A simple checklist of biological tests is insufficient. * **Strategic Approach:** 1. **Intensive Chemical Characterization:** The primary focus must be on a comprehensive extractables and leachables (E&L) study under aggressive and simulated-use conditions to identify and quantify all potential leachables. 2. **Rigorous Toxicological Risk Assessment:** Every identified leachable must be assessed by a qualified toxicologist to determine its potential risk to patients over a lifetime of exposure. 3. **Targeted Biological Testing:** The results of the chemical and toxicological assessments will inform the biological test plan. While some tests like cytotoxicity may still be necessary, the goal is to use the chemical data to justify forgoing long-term, burdensome animal studies where possible. 4. **Early Q-Submission:** Given the novelty, sponsors should engage FDA early via a Q-Submission to present the BEP and get feedback on the proposed chemical characterization and testing strategy. This can prevent significant delays later in the process. ### Scenario 2: A Legacy Device with a Change in Sterilization Method * **Challenge:** An existing device with a long history of safe use undergoes a seemingly minor process change, such as switching from ethylene oxide (EtO) to gamma sterilization. * **Strategic Approach:** 1. **Conduct a Gap Analysis:** The manufacturer cannot assume the existing biocompatibility data is still valid. The change in sterilization could alter the material's surface, potentially creating new chemical leachables or leaving different residuals. 2. **Re-Evaluate Chemical Profile:** A comparative chemical characterization study may be necessary to demonstrate that the new sterilization method does not introduce new or higher levels of toxicologically significant chemicals. 3. **Update the BER:** The Biological Evaluation Report must be updated to include an assessment of the change. This update should document the gap analysis, present any new data, and conclude whether the device's biological safety profile remains unchanged. 4. **Consider Confirmatory Testing:** Depending on the outcome of the chemical analysis, limited confirmatory biocompatibility testing (e.g., for cytotoxicity or residuals) may be prudent to confirm the assessment's conclusions. ## Strategic Considerations and the Role of Q-Submission A proactive and strategic approach is critical for navigating the evolving biocompatibility landscape. Manufacturers should view biocompatibility not as a final testing gate but as an integral part of the device design and development process. Engaging with the FDA through the Q-Submission program is an invaluable tool for de-risking a regulatory submission. This is particularly important when: * Using a novel material or manufacturing process. * The device has a complex risk profile. * The testing strategy relies heavily on chemical characterization and risk assessment to justify waiving standard biological tests. A Q-Submission allows a sponsor to present their BEP and overall strategy to the FDA and receive feedback before committing significant resources to testing. This early alignment can save invaluable time and resources and significantly increases the predictability of the final submission review. ## Finding and Comparing Biocompatibility Testing Services Providers Choosing the right partner for biocompatibility evaluation is a critical strategic decision. A qualified provider offers more than just testing services; they provide expertise in regulatory strategy, chemical analysis, and toxicology. When selecting a laboratory or consultant, manufacturers should look for: * **Accreditation and Compliance:** Ensure the facility is ISO/IEC 17025 accredited and operates under Good Laboratory Practice (GLP) standards as required. * **Integrated Expertise:** Look for a partner with in-house experts in chemistry, biology, and toxicology who can collaborate to develop a cohesive strategy, interpret complex data, and write a robust BER. * **Relevant Device Experience:** A provider with experience in similar device types and materials will better understand the potential challenges and regulatory expectations. * **Regulatory Familiarity:** The provider should have a deep understanding of current FDA guidance and international standards, including the anticipated changes to ISO 10993-1. Comparing providers based on these criteria helps ensure you select a partner who can support your entire biological risk assessment process, from initial planning to final report. To find qualified vetted providers [click here](https://cruxi.ai/regulatory-directories/biocompatibility_testing) and request quotes for free. ## Key FDA references When planning a biocompatibility program, sponsors should always refer to the latest versions of official regulatory documents. Key resources include: * FDA's guidance on the Use of International Standard ISO 10993-1, 'Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process'. * FDA's Q-Submission Program guidance for information on obtaining agency feedback. * Relevant sections of 21 CFR that govern medical device submissions and quality system regulations. This article is for general educational purposes only and is not legal, medical, or regulatory advice. For device-specific questions, sponsors should consult qualified experts and consider engaging FDA via the Q-Submission program. --- *This answer was AI-assisted and reviewed for accuracy by Lo H. Khamis.*